© 1999 by Society
© 1999 by the Society forNeuro-Oncology
Descriptive epidemiology of primary brain and CNS tumors: Results fromthe Central Brain Tumor Registry of the United States, 1990-1994
Division of Epidemiology and Biostatistics [T.S.S.,B.J.M., V.K., P.J.J., F.G.D.], School of Public Health, University of Illinoisat Chicago, IL 60612; and Department of Pathology[J.M.B.], M.D. Anderson Cancer Center, University of Texas, Houston, TX77030-4095
2 Address correspondence and reprint requests to Tanya Surawicz, Division ofEpidemiology and Biostatistics (M/C 922), School of Public Health, Universityof Illinois at Chicago, 2121 West Taylor Street, Chicago, IL 60612-7260.
 |
Abstract |
|---|
The Central Brain Tumor Registry of the United States (CBTRUS) obtained 5years of incidence data (1990-1994)—including reports on all primarybrain and CNS tumors—from 11 collaborating state cancer registries. Datawere available for 20,765 tumors located in the brain, meninges, and other CNSsites, including the pituitary and pineal glands. The average annual incidencewas estimated at 11.5 cases per 100,000 person-years. The higher incidence oftumors in male patients (12.1 per 100,000 person-years) than in femalepatients (11.0 per 100,000 person-years) was statistically significant(P<0.05); the higher incidence in whites (11.6 per 100,000person-years) compared with blacks (7.8 per 100,000 person-years) wasstatistically significant (P<0.05). The most frequently reportedhistologies were meningiomas (24.0%) and glioblastomas (22.6%). Higher ratesfor glioblastomas, anaplastic astrocytomas, oligodendrogliomas, anaplasticoligodendrogliomas, ependymomas, mixed gliomas, astrocytomas not otherwisespecified, medulloblastomas, lymphomas, and germ cell tumors in male than infemale patients were statistically significant (P<0.05), withrelative risks (RR) ranging from 1.3 to 3.4. Meningiomas were the only tumorswith a significant excess in females (RR=0.5). We noted higher occurrencerates in whites than in blacks for the following histologies: diffuseastrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas,ependymomas, mixed gliomas, astrocytomas NOS, medulloblastomas, nerve sheathtumors, hemangioblastomas, and germ cell tumors, with RRs ranging from 1.5 to3.4. Racial differences in occurrence rates were not observed forpredominately benign meningiomas or pituitary tumors. This study representsthe largest compilation of data on primary brain and CNS tumors in the UnitedStates. Standard reporting definitions and practices must be universallyadopted to improve the quality and use of cancer registry data.
Received July 22, 1998; Accepted October 1, 1998
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R.F. Barajas Jr, J.L. Rubenstein, J.S. Chang, J. Hwang, and S. Cha Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive of Clinical Outcome in Primary Central Nervous System Lymphoma AJNR Am. J. Neuroradiol., January 1, 2010; 31(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Taylor, C. Frobisher, D. W. Ellison, R. C. Reulen, D. L. Winter, R. E. Taylor, C. A. Stiller, E. R. Lancashire, E. C.G. Tudor, C. Baggott, et al. Survival After Second Primary Neoplasms of the Brain or Spinal Cord in Survivors of Childhood Cancer: Results From the British Childhood Cancer Survivor Study J. Clin. Oncol., December 1, 2009; 27(34): 5781 - 5787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujimaki Central Nervous System Germ Cell Tumors: Classification, Clinical Features, and Treatment With a Historical Overview J Child Neurol, November 1, 2009; 24(11): 1439 - 1445. [Abstract] [PDF]
|
|
|
|
 |
|
 S. H. Golden, K. A. Robinson, I. Saldanha, B. Anton, and P. W. Ladenson Prevalence and Incidence of Endocrine and Metabolic Disorders in the United States: A Comprehensive Review J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1853 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Smith, D. Zurakowski, A. Saad, R. M. Scott, and M. A. Moses Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy Clin. Cancer Res., April 15, 2008; 14(8): 2378 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Toh, M. Castillo, A.M.-C. Wong, K.-C. Wei, H.-F. Wong, S.-H. Ng, and Y.-L. Wan Primary Cerebral Lymphoma and Glioblastoma Multiforme: Differences in Diffusion Characteristics Evaluated with Diffusion Tensor Imaging AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 471 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cha, J.M. Lupo, M.-H. Chen, K.R. Lamborn, M.W. McDermott, M.S. Berger, S.J. Nelson, and W.P. Dillon Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inglese, S. Brown, G. Johnson, M. Law, E. Knopp, and O. Gonen Whole-Brain N-Acetylaspartate Spectroscopy and Diffusion Tensor Imaging in Patients with Newly Diagnosed Gliomas: A Preliminary Study AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2137 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cha, L. Yang, G. Johnson, A. Lai, M.-H. Chen, T. Tihan, M. Wendland, and W.P. Dillon Comparison of Microvascular Permeability Measurements, Ktrans, Determined with Conventional Steady-State T1-Weighted and First-Pass T2*-Weighted MR Imaging Methods in Gliomas and Meningiomas. AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hoffman, J. M. Propp, and B. J. McCarthy Temporal trends in incidence of primary brain tumors in the United States, 1985-1999 Neuro Oncology, January 1, 2006; 8(1): 27 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen, E. A. Knopp, H. Rusinek, J. S. Babb, D. Zagzag, and O. Gonen Assessing Global Invasion of Newly Diagnosed Glial Tumors with Whole-Brain Proton MR Spectroscopy AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2170 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen, E. A. Knopp, H. Rusinek, S. Liu, and O. Gonen Brain Compression without Global Neuronal Loss in Meningiomas: Whole-Brain Proton MR Spectroscopy Report of 2 Cases AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2178 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Fang, M. Kulldorff, and D. I. Gregorio Brain cancer mortality in the United States, 1986 to 1995: A geographicanalysis Neuro Oncology, July 1, 2004; 6(3): 179 - 187. [Abstract] [PDF]
|
|
|
|
|
|
S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher Phase 2 study of temozolomide and Caelyx in patients with recurrentglioblastoma multiforme Neuro Oncology, January 1, 2004; 6(1): 38 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 I-M. Siu, A. Lal, J. R. Blankenship, N. Aldosari, and G. J. Riggins c-Myc Promoter Activation in Medulloblastoma Cancer Res., August 15, 2003; 63(16): 4773 - 4776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of theliterature Neuro Oncology, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Jukich, B. J. McCarthy, T. S. Surawicz, S. Freels, and F. G. Davis Trends in incidence of primary brain tumors in the United States,1985-1994 Neuro Oncology, July 1, 2001; 3(3): 141 - 151. [Abstract] [PDF]
|
|
|
|
|
|
F. G. Davis, V. Kupelian, S. Freels, B. McCarthy, and T. Surawicz Prevalence estimates for primary brain tumors in the United States bybehavior and major histology groups Neuro Oncology, July 1, 2001; 3(3): 152 - 158. [Abstract] [PDF]
|
|